Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

Wang, Z; Jiang, LY; Yan, H; Xu, ZF; Luo, PH

Luo, PH (corresponding author), Zijingang Univ, Zijingang Campus,866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, ; ():

Abstract

Introduction: Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR/ABL, which is used for the first-line treatment of newly ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索